Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC

NCT00191139 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2003
Completion date
February 28, 2009
Enrollment
64 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer